The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025

Tuesday, February 19, 2019 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 18, 2019 /PRNewswire/ --

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025

Read the full report: The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025, according to a new report by Grand View Research,
Inc. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.Further key findings from the study suggest:• Diabetes segment led the market in 2017, in terms of revenue generation,owing to higher prevalence and drug usage• Obesity segment is expected to register a CAGR of 9.27% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes• Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases• The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis• Key companies in this market are Novo Nordisk A/S;Sanofi S.A.; BoehringerIngelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc.;Biocon Ltd.;BioMarinPharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.• Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position• Oral route of administration was the key revenue-generating segment in 2017owing to its benefits, such as high reliability and ease of administration• North America was the largest regional market in 2017 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesityRead the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store